David Arkowitz,MBA, joins Alkeus Pharmaceuticals as Chief Financial Officer
He also had previously served as the Chief Financial Officer for several companies in the biotechnology and pharmaceuticals space.
(Image credit: AdobeStock/Magic Art)
David Arkowitz, MBA, has joined Alkeus Pharmaceuticals as Chief Financial Officer.
Prior to joining Alkeus, Arkowitz served as Executive Vice President, Chief Financial Officer and Head of Business Development of Seres Therapeutics. He also had previously served as the Chief Financial Officer for several companies in the biotechnology and pharmaceuticals space, including Flexion Therapeutics (acquired by Pacira Biosciences), Visterra (acquired by Otsuka Pharmaceutical Co), Mascoma, AMAG Pharmaceuticals, and Idenix Pharmaceuticals. Within each of these companies, Arkowitz also held additional leadership positions.1
Arkowitz spent more than 13 years at Merck, where he was Vice President and Controller of the US pharmaceutical business, Controller of the global research and development division, and the Chief Financial Officer of Merck’s Canadian subsidiary.1
Arkowitz earned a BA in mathematics from Brandeis University and an MBA in finance from Columbia University Business School.
In the press release1 from Alkeus, Arkowitz shared a few of his thoughts on joining the company. He is quoted as saying, “I’m excited to join Alkeus at a pivotal time as the company prepares to potentially bring the first and much-needed oral therapy to market for Stargardt disease, where there is no approved treatment available. Alkeus is poised to make a meaningful difference in the lives of patients living with retinal diseases, and I’m honored to be a part of the team working to achieve this important mission.”
Michel Dahan, President and CEO of Alkeus Pharmaceuticals also spoke to the addition of Alkeus to the leadership of the company, saying “David is an experienced biopharma executive who brings to our team more than 30 years of finance, operations, business development and commercial leadership experience in the life sciences and biotech industries. In addition to his track record leading finance functions, David has extensive business development and commercial product launch experience, and we are thrilled to welcome him to the team.”1
In addition to his new appointment, Arkowitz currently serves on the board of directors of Kineta and has previously served on the boards of directors of F-star Therapeutics, Yumanity Therapeutics, Spring Bank Pharmaceuticals, Proteostasis Therapeutics, Aegerion Pharmaceuticals, and ImpactRx.1
